Clinical Trial Detail

NCT ID NCT01907815
Title Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

acute myeloid leukemia

Therapies

Trametinib + Uprosertib

Age Groups: adult

Additional content available in CKB BOOST